RecruitingEarly Phase 1

To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital

Pakistan106 participantsStarted 2025-12-25

Plain-language summary

This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients having age between 18-60 years of either gender Diagnosed with moderate to severe plaque psoriasis (PASI ≥10) No prior systemic therapy in past 3 months. Exclusion Criteria: Pregnancy or lactation History of liver or renal dysfunction Known hypersensitivity to study drugs

What they're measuring

PASI SCORE calculation

Timeframe: 3 months

Trial details

NCT IDNCT07337434

SponsorSyeda Sana Zaman

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2026-06-25

Contact for this trial

Filza Ajmal, FCPS part 2

+923008179226 binteajmal1996@gmail.com

View on ClinicalTrials.gov More Chronic Plaque Psoriasis trials